We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Economic Analysis In Off-Label Promotion Cases

Law360 (January 26, 2009, 12:00 AM EST) -- In an increasing number of government investigations, the central allegation is that a pharmaceutical manufacturer promoted one of its products off-label. Many of these investigations have resulted in hundreds of millions of dollars in payouts by drug companies.

The sheer number of these investigations and magnitude of settlements, as well as the complex regulatory, scientific and business environment in which prescription drug sales occur, suggest a key role for economic analysis.

Newly announced U.S. Food and Drug Administration regulations that permit pharmaceutical companies to distribute copies...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.